Study of CS-3150 in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1001 participants.

Also called NCT02890173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,001 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02890173
Other papers using this trial's data
  • Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study) Hypertension (Dallas, Tex. : 1979), 2020-01 DOI, PubMed 31786983

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02890173. Randomized; quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-07-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of CS-3150 in Patients With Essential Hypertension
Acronym
ESAX-HTN
Condition
Essential Hypertension
Intervention (Drug)
CS-3150
Intervention (Drug)
Eplerenone
Lead sponsor
Daiichi Sankyo Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02890173
Content hash
a6b537bd556b4b6f3f88445f5b875ab5cb60986f854b96423a6c65a97183d5b0